Adaptimmune Restructures Leadership to Advance Cell Therapy Strategy
Dateline: November 17, 2025 — Philadelphia, PA & Oxford, UKAdaptimmune Therapeutics plc announced significant Board and Executive Leadership changes,...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Dateline: November 17, 2025 — Philadelphia, PA & Oxford, UKAdaptimmune Therapeutics plc announced significant Board and Executive Leadership changes,...
